Search Results

Mycovia Pharmaceuticals, Inc., an emerging biopharmaceutical company, announced that patients now have exclusive access to VIVJOA® through AllianceRx Walgreens Pharmacy and Walgreens community-based specialty pharmacies, subsidiaries of Walgreens Boots Alliance, Inc.

Walgreens and Boehringer Ingelheim announced a strategic collaboration aimed at optimizing recruitment and making clinical trials more accessible, inclusive and equitable.

In an effort to improve diversity and accessibility in clinical trials, Boehringer Ingelheim is partnering with Walgreens to conduct a Phase III study in obesity and type 2 diabetes.

Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $400 million in a private transaction.

The retail pharmacy giant and the Biomedical Advanced Research and Development Authority hope to make decentralized clinical trials more accessible and representative of the U.S. population.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the first quarter of fiscal 2024, which ended November 30, 2023.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that its board of directors has declared a quarterly dividend of 25 cents per share, a reduction of 48 percent from the previous quarter.

Susan G. Komen®, the world’s leading breast cancer organization and Walgreens announced another milestone in the transformative five-year collaboration that has not only propelled groundbreaking research in breast cancer but has also significantly expanded access to essential breast health and breast cancer services, support and resources.

Verrica Pharmaceuticals Inc., a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, announced that it is growing its distribution network by entering into an agreement with Walgreen Co. to distribute YCANTH™ through its specialty pharmacy.